A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Clinical trial NCT02511405 · COMPLETED
Trial details
- NCT number
- NCT02511405
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-08-01
- Primary completion
- 2017-11-03
- Enrollment
- 252
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.